Related Experiment Video
Updated: Oct 28, 2025

BioMEMS: Forging New Collaborations Between Biologists and Engineers
Published on: November 1, 2007
A multi-institutional partnership catalyzing the commercialization of medical devices and biotechnology products
Nathaniel Hafer1,2,3, Bryan Buchholz2,4, Denise Dunlap2,5
1UMass Center for Clinical and Translational Science, Worcester, MA, USA.
Abstract:
The commercialization of medical devices and biotechnology products is characterized by high failure rates and long development lead times particularly among start-up enterprises. To increase the success rate of these high-risk ventures, the University of Massachusetts Lowell (UML) and University of Massachusetts Medical School (UMMS) partnered to create key academic support centers with programs to accelerate entrepreneurship and innovation in this industry. In 2008, UML and UMMS founded the Massachusetts Medical Device Development Center (M2D2), which is a business and technology incubator that provides business planning, product prototyping, laboratory services, access to clinical testing, and ecosystem networking to medical device and biotech start-up firms. M2D2 has three physical locations that encompass approximately 40,000 square feet. Recently, M2D2 leveraged these resources to expand into new areas such as health security, point of care technologies for heart, lung, blood, and sleep disorders, and rapid diagnostics to detect SARS-CoV-2. Since its inception, M2D2 has vetted approximately 260 medical device and biotech start-up companies for inclusion in its programs and provided active support to more than 80 firms. This manuscript describes how two UMass campuses leveraged institutional, state, and Federal resources to create a thriving entrepreneurial environment for medical device and biotech companies.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Clinical Trials: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Preclinical Development: Overview
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

